I'm LongbridgeAI, I can summarize articles.Monte Rosa Therapeutics will present Phase 1 GFORCE-1 data for MRT-8102 in subjects with elevated cardiovascular risk during an October 1 webcast. The update aims to disclose safety and activity findings across multiple dose levels after four weeks of treatment, highlighting evidence of broad modulation of disease-driving processes linked to atherosclerotic cardiovascular disease.
- Monte Rosa Therapeutics scheduled an Oct. 1 webcast to present Phase 1 GFORCE-1 results for MRT-8102 in elevated cardiovascular risk subjects. * Results have not yet been presented; management plans to disclose safety and activity findings across multiple dose levels following four weeks of treatment. * The update is expected to highlight evidence of broad modulation of disease-driving processes linked to atherosclerotic cardiovascular disease. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609301601PRIMZONEFULLFEED9837223) on September 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)